The use of spray-drying to enhance celecoxib solubility

Drug Development and Industrial Pharmacy

Volumn 37, Issue 12, 2011, Pages 1463-1472

  Fouad, Ehab A ^a,b   El Badry, Mahmoud ^a,b   Mahrous, Gamal M ^a   Alanazi, Fars K ^a   Neau, Steven H ^c   Alsarra, Ibrahim A ^a,d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

celecoxib; dissolution rate; Kollicoat IR ; polyethylene glycol; polyvinyl alcohol; Spray drying

Indexed keywords

CELECOXIB; DICHLOROMETHANE; MACROGOL 6000; POLYVINYL ALCOHOL; SOLVENT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; FOURIER TRANSFORM MASS SPECTROMETRY; HYDROGEN BOND; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; X RAY DIFFRACTION;

BIOLOGICAL AVAILABILITY; CYCLOOXYGENASE 2 INHIBITORS; DESICCATION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYVINYL ALCOHOL; POLYVINYLS; PYRAZOLES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFONAMIDES; SURFACE-ACTIVE AGENTS;

EID: 80955135462     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.587428     Document Type: Article

References (35)

1. Martin P, Bustamante A, Chun AHC. (1993). Physical Pharmacy. Philadelphia, PA: Lippincott Williams & Wilkins.
2. Geis GS. (1999). Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl, 109:31-37. (Pubitemid 29306630)
3. Fort J. (1999). Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop, 28:13-18.
4. Davies NM, Gudde TW, de Leeuw MA. (2001). Celecoxib: a new option in the treatment of arthropathies and amilial adenomatous polyposis. Expert Opin Pharmacother, 2:139-152. (Pubitemid 32427720)
5. Moore PA, Hersh EV. (2001). Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc, 132:451-456. (Pubitemid 33609914)
6. Tindall E. (1999). Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. J Am Osteopath Assoc, 99:S13-S17.
7. Tibble JA, Sigthorsson G, Foster R, Bjarnason I. (2000). Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol, 35:802-807.
8. Ayalasomayajula SP, Kompella UB. (2004). Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res, 21:1797-1804. (Pubitemid 39390091)
9. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B et al. (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther, 297:638-645. (Pubitemid 32377995)
10. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. (2006). Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci, 47:1149-1160. (Pubitemid 46768351)
11. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
12. Banga S, Chawla G, Varandani D, Mehta BR, Bansal AK. (2007). Modification of the crystal habit of celecoxib for improved processability. J Pharm Pharmacol, 59:29-39. (Pubitemid 46133041)
13. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. (2004). Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull, 27:1993-1999. (Pubitemid 41701577)
14. Dixit RP, Nagarsenker MS. (2007). In vitro and in vivo advantage of celecoxib surface solid dispersion and dosage form development. Indian J Pharm Sci, 69:370-377.
15. Nagarsenker MS, Joshi MS. (2005). Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev Ind Pharm, 31:169-178. (Pubitemid 40315712)
16. Gupta VR, Mutalik S, Patel MM, Jani GK. (2007). Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties. Acta Pharm, 57:173-184. (Pubitemid 46761981)
17. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR et al. (2007). Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci, 96:2686-2702. (Pubitemid 47597818)
18. Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29:278-287. (Pubitemid 44740131)
19. Kolter K. (2002). Kollicoat IR®-innovation in instant release film coating. BASF ExAct, 8:4-5.
20. Punitha S, Karthikeyan D, Devi P, Vedha Hari BN. (2009). Enhancement of solubility and dissolution of celecoxib by solid dispersion technique. J Pharm Sci Technol, 2:63-68.
21. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. (2003). Characterization of solid-state forms of celecoxib. Eur J Pharm Sci, 20:305-317. (Pubitemid 37338536)
22. Thimmasetty J, Subrahmanyam CVS, Vishwanath BA, Sathesh Babu PR. (2009). Solubility parameter estimation of celecoxib by current methods. Asian J Res Chem, 2:188-195.
23. Vasu Dev R, Shashi Rekha K, Vyas K, Mohanti SB, Rajender Kumar P, Om Reddy G. (1999). Celecoxib, a COX-II inhibitor. Acta Cryst, C55:IUC9900161 [doi:10.1107/S0108270199098200].
24. Qian XF, Yin J, Guo XX, Yang YF, Zhu ZK, Lu J. (2000). Polymer- inorganic nanocomposites prepared by hydrothermal method: PVA/ZnS, PVA/CdS, preparation and characterization. J Mater Sci Letters, 19:2235-2237. (Pubitemid 32873965)
25. Biswal S, Sahoo J, Murthy PN. (2009). Characterization of gliclazide- PEG 8000 solid dispersions. Trop J Pharm Res, 8:417-424.
26. Gupta P, Bansal AK. (2005). Devitrification of amorphous celecoxib. AAPS Pharmscitech, 6:E223-E230. (Pubitemid 41631749)
27. Puria V, Dantuluria AK, Kumarb M, Kararb N, Bansal AK. (2010). Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci, 40:84-93.
28. Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactoneloaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35:297-304.
29. Shimpi SL, Mahadik KR, Paradkar AR. (2009). Study on mechanism for amorphous drug stabilization using gelucire 50/13. Chem Pharm Bull, 57:937-942.
30. Dordunoo SK, Ford JL, Rubinstein MH. (1991). Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm, 17:1685-1713.
31. Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47-60. (Pubitemid 30326688)
32. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C et al. (2002). Characterization of carbamazepine- gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci, 91:699-707. (Pubitemid 34639633)
33. Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1-12.
34. El-Badry M, Fetih G, Fathy M. (2009). Improvement of solubility and dissolution rate of indomethacin by solid dispersions in gelucire 50/13 and PEG4000. Saudi Pharm J, 17:217-225.
35. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. (2007). Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm, 66:334-347. (Pubitemid 46778978)